Cardiovascular Research Advance Access [Accepted Manuscript] published online on June 9, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn154
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Post-Infarct Treatment with an Erythropoietin-Gelatin Hydrogel Drug Delivery System for Cardiac Repair
Department of Cardiology, Gifu University Graduate School of Medicine, Yanagido 1-1, Gifu 5011194, Japan
Address correspondence to: Shinya Minatoguchi, M.D., PhD Department of Cardiology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 5011194, Japan Phone: +81-58-230-6520 Fax: +81-58-230-6524 E-mail: minatos{at}gifu-u.ac.jp
Aims: We investigated the effect of an erythropoietin (EPO)-gelatin hydrogel drug delivery system (DDS) applied to the heart on myocardial infarct (MI) size, left ventricular (LV) remodeling and function.
Methods and Results: Experiments were performed in a rabbit model of myocardial infarction. The infarct size was reduced, and LV remodeling and function were improved 14 days and 2 months after MI but not at 2 days after MI in the EPO-DDS group. The number of cluster of differentiation 31(CD31)-positive microvessels and the expression of erythropoietin receptor (EPO-R), phosphorylated-Akt (p-Akt), phosphorylated glycogen synthase kinase 3β (p-GSK-3β), phosphorylated extracellular signal-regulated protein kinase (p-ERK), phosphorylated signal transducer and activator of transcription 3 (p-Stat3), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-1 (MMP-1) were significantly increased in the myocardium of the EPO-DDS group.
Conclusions: Post-MI treatment with an EPO-DDS improves LV remodeling and function by activating prosurvival signaling, antifibrosis and angiogenesis without causing any side effect.
Time for primary review: 25 days
* Kyoto Women's University, Kyoto, Japan.
** Kyoto University, Kyoto, Japan
Related Article
CiteULike 
Connotea 
Del.icio.us What's this?
Cardiovasc Res 2008 79: 549-550.
This article has been cited by other articles:
|
|
 |
|
  M. Kurdi and G. W. Booz JAK redux: a second look at the regulation and role of JAKs in the heart Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1545 - H1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Ding, Q. Wang, J. Deng, Q. Gu, S. Hu, Y. Li, B. Su, Y. Zeng, and L. Xiong Sevoflurane Preconditioning Induces Rapid Ischemic Tolerance Against Spinal Cord Ischemia/Reperfusion Through Activation of Extracellular Signal-Regulated Kinase in Rabbits Anesth. Analg., October 1, 2009; 109(4): 1263 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, H. Okada, G. Takemura, M. Esaki, H. Kobayashi, H. Kanamori, I. Kawamura, R. Maruyama, T. Fujiwara, H. Fujiwara, et al. Sustained Release of Erythropoietin Using Biodegradable Gelatin Hydrogel Microspheres Persistently Improves Lower Leg Ischemia J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2378 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Mehta Erythropoietin in cardioprotection: does it have a future or is it all in the past? Cardiovasc Res, September 1, 2008; 79(4): 549 - 550. [Full Text] [PDF]
|
|